COVID-19 Drug Delivery Devices

Global COVID-19 Drug Delivery Devices Market to Reach US$1.6 Billion by 2030

The global market for COVID-19 Drug Delivery Devices estimated at US$1.6 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of -0.1% over the analysis period 2024-2030. Prefilled Syringe, one of the segments analyzed in the report, is expected to record a 0.0% CAGR and reach US$790.6 Million by the end of the analysis period. Growth in the Needle-free Injectors segment is estimated at -0.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$445.8 Million While China is Forecast to Grow at 0.1% CAGR

The COVID-19 Drug Delivery Devices market in the U.S. is estimated at US$445.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$276.8 Million by the year 2030 trailing a CAGR of 0.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -0.2% and -0.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -0.2% CAGR.

Global COVID-19 Drug Delivery Devices Market – Key Trends & Drivers Summarized

How Has the Pandemic Transformed Drug Delivery? Understanding the Shift in Healthcare Priorities

The COVID-19 pandemic has reshaped the global healthcare industry, accelerating the demand for advanced drug delivery devices to ensure efficient and safe administration of antiviral treatments and vaccines. The rapid development and distribution of COVID-19 vaccines necessitated the expansion of syringe and auto-injector manufacturing, leading to unprecedented growth in the drug delivery devices market. Additionally, the surge in hospitalized COVID-19 patients required improved inhalation and nebulization therapies for managing respiratory complications. The pandemic also underscored the importance of self-administered drug delivery solutions, prompting a shift toward prefilled syringes, autoinjectors, and wearable drug delivery systems. Telemedicine integration and at-home healthcare solutions have further increased demand for smart drug delivery devices that enable remote monitoring and dosage tracking. Additionally, the rising emphasis on global pandemic preparedness has prompted governments and pharmaceutical companies to invest in scalable and efficient drug delivery infrastructure.

Which Drug Delivery Devices Have Seen the Highest Demand? Exploring Key Product Segments

The COVID-19 drug delivery devices market comprises various segments, including syringes, inhalers, autoinjectors, infusion pumps, and transdermal patches. Prefilled syringes have been one of the most critical components in vaccine administration, with manufacturers ramping up production to meet global demand. Inhalation drug delivery systems, including nebulizers and dry powder inhalers, have played a crucial role in managing COVID-19-related respiratory complications, particularly among high-risk patients. Wearable drug delivery devices, such as insulin pumps and smart injectors, have gained traction as patients seek contactless and self-administered treatment solutions. Additionally, the emergence of microneedle patches for vaccine delivery has introduced a novel alternative to traditional injections, reducing the need for cold-chain storage and improving accessibility in remote regions. The shift toward needle-free drug delivery systems has also accelerated, driven by concerns over needle-stick injuries and patient compliance.

How Is Innovation Revolutionizing COVID-19 Drug Delivery? The Role of AI, Nanotechnology & Smart Devices

The pandemic has driven a wave of technological innovations in drug delivery devices, leading to the development of more efficient, patient-friendly solutions. AI-driven inhalers equipped with real-time symptom tracking have enhanced respiratory treatment adherence, particularly for long-term COVID-19 complications. The integration of nanotechnology in drug delivery has improved the bioavailability and targeted action of COVID-19 therapeutics, minimizing side effects and optimizing treatment outcomes. Additionally, smart drug delivery devices with remote connectivity features have facilitated remote patient monitoring, reducing hospital visits and improving healthcare accessibility. The development of temperature-stable vaccine formulations, combined with needle-free delivery systems, has addressed logistical challenges associated with mass immunization campaigns. Furthermore, advancements in biopharmaceuticals have led to the creation of long-acting antiviral formulations, reducing the frequency of drug administration and enhancing treatment efficacy.

What’s Driving the Growth of the COVID-19 Drug Delivery Devices Market? Key Market Influencers Explained

The growth in the COVID-19 drug delivery devices market is driven by several factors, including increased global immunization efforts, advancements in drug delivery technology, and the expansion of self-administered treatment options. The rising investment in biopharmaceuticals has accelerated the development of next-generation drug delivery solutions, improving patient compliance and therapeutic outcomes. The expansion of e-commerce and digital healthcare platforms has also facilitated the widespread availability of self-administration drug delivery devices. Additionally, government initiatives aimed at pandemic preparedness have led to increased funding for scalable vaccine distribution and emergency medical supply chains. The shift toward personalized medicine and targeted drug delivery approaches has further strengthened market growth. As the healthcare industry continues to evolve post-pandemic, the COVID-19 drug delivery devices market is expected to expand, driven by innovation, digital integration, and enhanced global healthcare infrastructure.

SCOPE OF STUDY:

The report analyzes the COVID-19 Drug Delivery Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Prefilled Syringe, Needle-free Injectors, Inhalers, Patches); Route of Administration (Parenteral Administration, Nasal Administration, Other Administrations); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• ApiJect Systems Corp.
• AstraZeneca plc
• Becton, Dickinson and Company (BD)
• Bharat Biotech
• CanSino Biologics Inc.
• Cardinal Health
• Croda International Plc
• Gerresheimer AG
• GlaxoSmithKline plc (GSK)
• Hindustan Syringes & Medical Devices Ltd.
• Inovio Pharmaceuticals
• Johnson & Johnson
• Moderna, Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• SCHOTT AG
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.